Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: Risks versus benefits review

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 6, 2013, Pages 624-628

  Zimmerman, Deborah L ^c   Harmon, John P ^a   Zimmerman, Danielle L ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

anticoagulant; antiplatelet; vascular access

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROTEIN C; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERIOVENOUS FISTULA; BLOOD VESSEL CALCIFICATION; BRAIN ISCHEMIA; CHRONIC KIDNEY DISEASE; GRAFT PATENCY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); VASCULAR ACCESS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETERIZATION, CENTRAL VENOUS; HUMANS; KIDNEY FAILURE, CHRONIC; PLATELET AGGREGATION INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; STROKE; VASCULAR ACCESS DEVICES;

EID: 84887015949     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328365adca     Document Type: Review

References (42)

1. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med 2012; 172:623-631.
2. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from the randomised controlled trials. Lancet 2009; 373:1849-1860.
3. Zimmerman D, Sood MM, Rigatto C, et al. Systematic review and metaanalysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27:3816-3822.
4. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 Suppl):S16-S23.
5. Lo DS, Rabbat CG, Clase CM. Thromboembolism and anticoagulant management in hemodialysis patients: a practical guide to clinical management. Thromb Res 2006; 118:385-395.
6. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705-711.
7. Holden RM, Clase CM. Use of warfarin in people with low glomerular filtration rate or on dialysis. Semin Dial 2009; 22:503-511.
8. Seliger SL, Gillen DL, Longstreth WT, et al. Elevated risk of stroke among patients with end stage renal disease. Kidney Int 2003; 64:603-609.
9. Maringh R, Lane DA, Lip GYH. Severe renal impairment and stroke prevention in atrial fibrillation. J Am Coll Cardiol 2011; 57:1339-1348.
10. Kaw D, Malhotra D. Hematolgy: issues in the dialysis patient: platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19:317-322.
11. Iseki K, Kinjo K, Kimura Y, et al. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 1993; 44:1086-1090.
12. Sood P, Sinson GP, Cohen EP. Subdural hematomas in chronic dialysis patients: significant and increasing. Clin J Am Soc Nephrol 2007; 2:956-959.
13. Power A, Hamady M, Singh S, et al. High but stable incidence of subdural haematoma in haemodialysis: a single-centre study. Nephrol Dial Transplant 2010; 25:2272-2275.
14. Yang JY, Lee TC, Montez-Rath ME, et al. Trend in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 2012; 23:495-506.
15. Goldstein BA, Arce CM, Hlatky MA, et al. Trend in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 2012; 126:2293-2301.
16. Winkelmayer WC, Liu J, Ratrick AR, et al. Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. J Nephrol 2012; 25:341-353.
17. Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002; 13:2331-2337.
18. Wilkieson TJ, Ingram AJ, Crowther MA, et al. Low-intensity adjusted warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clin J Am Soc Nephrol 2011; 6:1018-1024.
19. Coli L, Donati G, Cianciolo G, et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheter (TCC) thrombosis. J Vasc Access 2006; 7:118-122.
20. Abdul-Rahman IS, Ah-Howaish AK. Warfarin versus aspirin in preventing tunneled hemodialysis catherer thrombosis: a prospective randomized study. Hong Kong J Nephrol 2007; 9:23-30.
21. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007; 50:433-440.
22. Phelan PJ, O'Kelly P, Holian J, et al. Warfarin use in hemodialysis patients: what is the risk? Clin Nephrol 2011; 75:204-211.
23. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010; 56:823-831.
24. Holden RM, Morton AR, Garland JS, et al. Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:590-597.
25. Praehauser C, Grandjean R, Steiger J, Mayr M. Cohort study on the quality of oral anticoagulation therapy in chronic haemodialysis patients treated with phenprocoumon. Swiss Med Wkly 2013; 143:w13730.
26. To AC, Yehia M, Collins J. Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply? Nephrology 2007; 12:441-447.
27. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20:2223-2233.
28. Holden RM, Sanfilippo AS, Hopman WM, et al. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol 2007; 20:417-422.
29. Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 2012; 27:1580-1584.
30. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associated with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20:872-881.
31. Ethier J, Bragg-Gresham JL, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2007; 50:602-611.
32. Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease [review]. Cochrane Database Syst Rev 2013; 28; CD008834. doi:10.1002/14651858.CD008834.pub2
33. Hiremath S, Holden RM, Fergusson D, Zimmerman D. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol 2009; 4:1347-1355.
34. Coleman CI, Tuttle LA, Teevan C, et al. Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta-analysis. Int J Clin Pract 2010; 64:1239-1244.
35. Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis. A randomized controlled trial. J Am Med Assoc 2008; 299:2164-2171.
36. Dixon BS, Beck GJ, Vazquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009; 360:2191-2201.
37. Dixon BS, Beck GJ, Dember LM, et al. Use of aspirin associated with longer primary patency of hemodialysis grafts. J Am Soc Nephrol 2011; 22:773-781.
38. Saran R, Dykstra DM, Wolfe RA, et al. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2002; 40:1255-1266.
39. Yevzlin AS, Conley EL, Sanchez RJ, et al. Vascular access outcomes and medication use: a USRDS study. Semin Dial 2006; 19:535-539.
40. Daimon S, Terai H. Influence of antiplatelet medication on bleeding events in hemodialysis patients. Ther Apher Dial 2011; 15:454-459.
41. Holden RM, Harman GJ, Wang M, et al. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:105-110.
42. Kaufman JS, O'Connor TZ, Ahang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14:2313-2321.